GO
Loading...

Health Care

More

  • Cigna's expansion strategy  Tuesday, 13 Jan 2015 | 10:17 AM ET

    David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.

  • Chimerix tackles Ebola outbreak  Tuesday, 13 Jan 2015 | 11:46 AM ET

    Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.

  • Valeant CEO: Allegations about our business not true  Tuesday, 13 Jan 2015 | 12:46 PM ET

    Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.

  • The U.K.’s National Health Service, for decades a global case-study in universal healthcare, seems to be facing its biggest ever crisis of confidence.

  • Sass bets on airline, hedge fund stock Monday, 12 Jan 2015 | 12:00 AM ET
    A ground crewmember prepares to push back an American Airlines Boeing 737-823 jet at a terminal at  Miami International Airport.

    Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.

  • I am a better person: Sam Waksal  Tuesday, 13 Jan 2015 | 8:36 AM ET

    Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.

  • J&J CEO: Too early to fully assess Obamacare  Monday, 12 Jan 2015 | 5:43 PM ET

    Alex Gorsky, Johnson & Johnson chairman and CEO, discusses how the ACA and the recovery in the economy is impacting business.

  • Shire CEO: $5.2 billion NPS deal will pay off  Monday, 12 Jan 2015 | 5:16 PM ET

    Flemming Ornskov, Shire CEO, tells CNBC's Meg TIrrell it is the right time for the proposed acquisition of NPS Pharmaceuticals.

  • Merck CEO: Deals create value  Monday, 12 Jan 2015 | 4:27 PM ET

    Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.

  • Biogen Idec beefs up pain pipeline  Monday, 12 Jan 2015 | 3:16 PM ET

    Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.

  • Targeting cancer's metabolism  Monday, 12 Jan 2015 | 2:46 PM ET

    Dr. David Schenkein, Agios CEO, explains a cancer's metabolism, and the company's priorities for 2015.

  • Bluebird's catalysts in 2015  Monday, 12 Jan 2015 | 1:44 PM ET

    Bluebird Bio CEO Nick Leschly, provides insight to how gene therapy can work to treat blood disorders, and sickle cell anemia.

  • Actavis CEO: Good can come from activists  Monday, 12 Jan 2015 | 12:38 PM ET

    Brent Saunders, Actavis CEO, discusses the deal environment, the process of acquiring Allergan and the good that comes from activist investors.

  • Celgene CEO: Creating a great future  Monday, 12 Jan 2015 | 11:45 AM ET

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.

  • Analyzing Eli Lilly's drug pipeline  Monday, 12 Jan 2015 | 10:15 AM ET

    CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.

  • The great Obamacare-Medicaid bait 'n' switch Monday, 12 Jan 2015 | 2:21 PM ET

    More and more Americans are "covered," but fewer and fewer Americans will actually be able to get health care, says Jake Novak. Here's why.

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • $1.8B drug deal to target cancer at genetic level Monday, 12 Jan 2015 | 8:05 AM ET

    Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."

  • Goldman Sachs: Watch out for energy M&A in 2015 Monday, 12 Jan 2015 | 7:14 AM ET
    A derrick hand removes the the plastic caps off the threaded ends of pipe used in the drilling process in Knox County, Ohio.

    Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.

  • Shire buys NPS Pharma in $5.2 billion deal Sunday, 11 Jan 2015 | 12:08 PM ET

    Shire said it will acquire NPS Pharmaceuticals in an all-stock transaction for about $5.2 billion, the companies said on Sunday.

Contact Health Care

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.